Vicks expands Sinex portfolio to offer targeted solutions to treat sinus symptoms
“The Clear Your Head Medicine” is poised to lead the sinus category, offering clarity in a confusing allergy and cold aisle.
Sinus sufferers can now breathe a sigh of relief as Vicks, the makers of NyQuil and DayQuil, has announced the relaunch and expansion of its Sinex brand, a complete line of over-the-counter (OTC) medications designed for consumers who suffer from sinus symptoms. With the relaunch, “The Clear Your Head Medicine” enters a misunderstood category to offer consumers a clear choice for their nasal congestion and pressure relief, regardless of whether symptoms are due to allergies, colds or other triggers.
Consumers can experience confusion when they’re trying to find a product that can offer total sinus relief, partly because our research has found that sinus lacks a true category leader. Without that well-known, go-to sinus brand, people are left to juggle a variety of products to find relief for their symptoms,” explained Dave Tomasi, Commercial Director, P&G Personal Health Care. “With 63% of sinus sufferers looking to a variety of medications that might not do the job for their sinus symptoms, this expansion of the Sinex line will offer one-stop-shop relief from a trusted brand.”
Seventy-one percent of US households (85 million) suffer from sinus symptoms in a given year, while 17% of US households (20 million) are severe sinus sufferers. This relaunch marks more than 50 years of the Vicks presence in the OTC sinus segment and more than 100 years as a trusted cough, cold and flu brand. Available this month, Vicks Sinex now offers a complete product lineup with both sprays and LiquiCaps including
Originally, launched in 1959 as “Medi Mist,” the brand adopted the name Sinex 3 years later and was the market leader through the mid-1990s. Although additional products have since entered the nasal spray market, Sinex has retained high awareness and a loyal following due to its “long-lasting relief” claim and the introduction of the first Ultra Fine Mist in the 1990s. Since the mid-90s, the brand has offered fast-acting relief in nasal spray form.
“There are many well-established brands for allergy relief but without that true category leader for consumers who suffer from sinus symptoms, it made sense to launch a line specifically designed to address these consumers’ needs, regardless of the trigger. We want to keep it simple – Sinex stands for sinus,” added Dave Tomasi.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance